PS.
PublicSupply
account_balanceBuyersbusinessSuppliersdescriptionNoticescategoryCategories
BuyersSuppliersNoticesCategories
verified_userData sourced from Contracts Finder, Find a Tender, and Companies House.
Contracts Finder ↗Find a Tender ↗Procurement Act 2023 ↗
  1. Home›
  2. Suppliers›
  3. Gilead Sciences Ltd
GS

Gilead Sciences Ltd

London
Large

Gilead Sciences Ltd is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines in areas such as virology, oncology, and inflammation.

gilead.com ↗

Summary from the supplier’s website — unverified

Compare peers
Awarded
£622.9m
Live
37
Buyers
13
12m
£161.5m
At a glance
  • Quick answer
Profile
  • Social value
  • ESG & policies
  • Capabilities6
  • Buyer references
  • Accreditations
Track record · verified
  • KPI performance
  • Contracts37 / 75
  • Top buyers13
  • Category mix
  • Geography
  • Peers5
Trust & risk
  • Red flags0
  • Compliance
  • Modifications
  • News
Company
  • Companies House
  • Financial
  • Org tree
Quick answer — Gilead Sciences LtdUpdated 20 Jul 2026

At a glance · for buyers and watchdogs

Gilead Sciences Ltd has won £622.9m across 13 public-sector buyers, with 37 live contracts. No active Companies House risk flags.

Why: top buyer NHS England at 75% · 0 active risk flags · 0 modifications.

Decision signals
0Active red flags
ActiveCompany status
37 of 75Live contracts
75%Top-buyer concentration
—Category exposure
0Contract modifications
If you're a buyer:CapabilitiesReferencesKPIComplianceWatchdog?FlagsModificationsConcentrationNews

Social value · 1/5

Commitments mapped to the Government Social Value Model themes. Each is tagged self-reported or from the website.

◐ From supplier website
JobsNo commitment stated✓
SkillsNo commitment stated✓
EnvironmentNo commitment stated✓
Tackling inequalityNo commitment stated✓
Community1 commitment ↗✓
Community · 1
  • WebsiteCorporate ResponsibilityGilead is committed to corporate responsibility and sustainability, focusing on health equity and community support.

Extracted automatically from gilead.com on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.

ESG & policies vault · 0/5

Key governance & sustainability policies. Published documents link out; missing ones are greyed.

↔ Cross-checked
Net-zero planNot provided✓
Modern slavery statementNot provided✓
EDI policyNot provided✓
Anti-briberyNot provided✓
Data protectionNot provided✓

Capabilities

What this supplier does, where they sit, who they sell to.

◐ From website & notices
Services · 2
ResearchGilead conducts research in various therapeutic areas including virology, oncology, and inflammation. ↗MedicinesGilead develops and provides access to medicines for various diseases. ↗
Frameworks & DPS · 6 from notices
  • Contract for the Supply of RemdesivirDepartment of Health and Social Care (T&T) · £21.5m
  • NHS England Framework Agreement: South of England (Tranche B)NHS England · £15.7m
  • NHS Framework Agreement, Branded Medicines for London and South of EnglandNHS England · £13.3m
  • NHS Framework Agreement for Proprietary Pharmaceuticals - South of England (Tranche A)NHS England · £10.5m
  • NHS England - Midlands and East Branded Medicines - Tranche BNHS England · £9.2m
  • NHS Framework Agreement for Branded medicines - London - Tranche B - Contracts Finder OpportunityNHS England · £8.4m

Extracted automatically from gilead.com on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.

Case studies

Delivery stories the supplier has published, with sector and outcome.

⚑ Self-reported
—

No case studies yet

Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.

Buyer references

Named public-sector contacts who have agreed to act as a reference.

✓ Confirmed by buyer
—

No buyer references yet

Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.

Accreditations & memberships

Independently issued. Verification dates cross-checked against issuer registers.

↔ Cross-checked
—

No accreditations recorded

B-Corp, ISO, Cyber Essentials, Living Wage and similar credentials appear here once added by a claimed supplier and cross-checked against the issuing register.

KPI performance

Delivery, budget and satisfaction scores reported quarterly by buyers.

✓ Verified
84

No verified KPI scores yet

Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.

Contracts · 37 live · 38 historic

Pulled from Contracts Finder & Find a Tender. Most recent first.

✓ From notices
TitleBuyerCPVAwardedValueTermStatus
Remdesivir infusion
Southern Health and Social Care Trust—14 May 2026£300k3 yrsLive
Biktarvy
Southern Health and Social Care Trust—13 May 2026£1.2m3 yrsLive
NHS England procurement for the supply of Pan-genotypic Direct Acting Antiviral (DAA) Hepatitis C treatments and the provision of Hepatitis C elimination initiatives
NHS England—01 Apr 2026£160.0m2 yrspending
NHS Framework for the supply of Licensed Antiretroviral Therapy (ART) 1 Nov 2024
NHS England3360000001 Nov 2024£48.2m2 yrsLive
NHS National Framework for Transition products commencing 1 October 2024
NHS England3360000001 Oct 2024£1.4m1.7 yrsClosed
NHS London Branded Medicines - Tranche B - September 2023
NHS England3360000001 Sept 2023£6.4m2 yrsClosed
NHS Midland & East Branded Medicines, Tranche B & Annual Tranche
NHS England3360000001 Mar 2023£13.7m2 yrsClosed
Supply of Remdesivir
Department of Health and Social Care (T&T)3360000031 Mar 2022£17.3m3 moClosed
Supply of Remdesivir
Department of Health and Social Care (T&T)3360000028 Feb 2022£5.7m4 moClosed
NHS Framework for the North of England, Branded Medicine
NHS England3360000001 Mar 2022£7.7m2 yrsClosed
Total live value £49.7m · mean award £8.3m1–10 of 75

Top buyers · 13 buyers · top 3 = 99%

Share of awarded value. Concentration fires above 40% for any single buyer.

✓ From notices
1
NHS England
31 contracts
75%
since 2017
2
Department of Health and Social Care (T&T)
11 contracts
22%
since 2020
3
NHSE&I
1 contract
2%
since 2022
4
Southern Health and Social Care Trust
6 contracts
0%
since 2026
5
The Clatterbridge Cancer Centre NHS Foundation Trust
2 contracts
0%
6
Leeds Teaching Hospitals NHS Trust
1 contract
0%
7
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
12 contracts
0%
8
NHS Scotland
1 contract
0%
9
Velindre NHS Trust, NHS Shared Services Partnership - Procurement Services (on behalf of All Wales Health Boards and Trusts)
4 contracts
0%
10
BELFAST HEALTH AND SOCIAL CARE TRUST
2 contracts
0%

Geography

Distribution of awarded value by buyer region.

✓ From notices
UK · schematic only
Yorkshire32 contracts
99%
Northern Ireland9 contracts
1%
North West4 contracts
0%
Scotland14 contracts
0%
Wales4 contracts
0%
Region resolved for 76% of awarded value (by buyer postcode); the remainder lacks a usable address.

Peers

Suppliers with overlapping CPVs & buyers (last 24m). Gilead Sciences Ltd highlighted.

✓ From notices
SupplierSME?Awarded · 24mContracts
GS
Gilead Sciences Ltd
No£161.5m—
DR
Dr Reddy's Laboratories (UK) Ltd
Yes£121.0m22
JA
Janssen-Cilag Ltd
Yes£117.6m18
AB
AbbVie Ltd
Yes£95.2m12
TA
Thornton and Ross Ltd
Yes£72.5m12
AC
ACCORD-UK LTD
Yes£71.2m21
Compare peers →

Red flags · 0 active

Automated scan of Companies House status, charges and insolvency records.

✓ Verified
✓ Clean. No active risk signals from Companies House status, charges or insolvency records.

Compliance scorecard

Derived from Companies House filings — not a full supplier-assurance check.

↔ Cross-checked
Trading status
Active
Live at Companies House
Annual accounts
Up to date
Last made up to 31 Dec 2024
Confirmation statement
Up to date
Next due 08 Apr 2027
Outstanding charges
0
No charges registered
Insolvency history
None
No insolvency cases registered
Certifications (ISO, Cyber Essentials, Living Wage, B-Corp, modern-slavery) are supplier self-reported and appear once a claimed profile adds them.

Modifications

Variations to awarded contracts logged under Procurement Act 2023 s.74.

✓ From notices
±

No modifications recorded

No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.

News mentions

UK trade press & nationals, matched to this supplier.

◰

No news mentions found

We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.

Companies House

Live sync — registered details, directors, PSC and SIC codes.

✓ Live sync

Registered details

Company no.
02543818
Status
Active
Type
Private limited
Incorporated
27 Sept 1990
Reg. office
280 High Holborn, London, WC1V 7EE
SIC codes
46460
Last accounts
31 Dec 2024
Next accounts due
30 Sept 2026

Directors & PSC

  • MARIN-LAZARO, Juan Peche — director
    Appointed 03 Mar 2025
  • WICKERSHAM, Peter — director
    Appointed 24 Oct 2024
  • YANG COMISKEY, Josephine — director
    Appointed 24 Oct 2024
  • MCKENZIE, Ian — secretary
    Appointed 23 Jun 2023
  • STÜCKER, Hans York-Julian — director
    Appointed 23 Jun 2023
  • Gilead Sciences, Inc. — person with significant control
    ownership of shares 75 to 100 percent · voting rights 75 to 100 percent · right to appoint and remove directors

Financial

Filed accounts from Companies House.

↔ From Cos House
£

No financial filings on record

Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.

Org tree

Group structure and ownership.

↔ From Cos House
GILEAD SCIENCES LTD
02543818 · this company

Independent. No parent company or subsidiaries recorded at Companies House for this entity.